NICE issues guidelines restricting NHS use of Roche’s idiopathic pulmonary fibrosis treatment, Esbriet
NICE have issued final guidelines endorsing the use of Roche’s Esbriet to treat patients with idiopathic pulmonary fibrosis (IPF) in England and Wales, but only for those with moderate to severe forms of the disease. The cost regulators are sticking with its position that Esbriet should only be funded by the NHS if the person